TY - JOUR
T1 - Blastoid Mantle Cell Lymphoma
AU - Jain, Preetesh
AU - Wang, Michael
N1 - Funding Information:
P. Jain: none. M. Wang: stock or othe ownership in MoreHealth; honoraria from Pharmacyclics, Janssen, AstraZeneca/Acerta Pharma, Targeted Oncology, and OMI; consultancy or advisory role for Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta Pharma, MoreHealth, Loxo Oncology, Kite, a Gilead Company, and Pulse Biosciences; research funding from Pharmacyclics, Janssen, AstraZeneca/Acerta Pharma, BioInvent, Novartis, Kite, a Gilead Company, Juno, Celgene, Loxo Oncology, and VelosBio; expert testimony for AstraZeneca/Acerta Pharma; and travel support from Janssen, Pharmacyclics, Celgene, Targeted Oncology, and OMI.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/10
Y1 - 2020/10
N2 - Blastoid and pleomorphic mantle cell lymphoma (MCL) are among the worst prognostic, aggressive histology, high-risk variants of MCL, and, in this article, they are presented as blastoid MCL. Blastoid MCL have not been systematically studied, probably due to their rarity. De novo blastoid MCLs have superior outcomes compared with transformed MCL. Compared with classic MCL, extranodal involvement (mainly skin, central nervous system), frequent relapses, and inferior responses to conventional chemoimmunotherapy, BTK inhibitors and venetoclax are frequent in blastoid MCL. KTE-X19 induces excellent response in blastoid MCL. Combinations with novel agents are actively investigated. This article presents a comprehensive review on blastoid MCL in 2020.
AB - Blastoid and pleomorphic mantle cell lymphoma (MCL) are among the worst prognostic, aggressive histology, high-risk variants of MCL, and, in this article, they are presented as blastoid MCL. Blastoid MCL have not been systematically studied, probably due to their rarity. De novo blastoid MCLs have superior outcomes compared with transformed MCL. Compared with classic MCL, extranodal involvement (mainly skin, central nervous system), frequent relapses, and inferior responses to conventional chemoimmunotherapy, BTK inhibitors and venetoclax are frequent in blastoid MCL. KTE-X19 induces excellent response in blastoid MCL. Combinations with novel agents are actively investigated. This article presents a comprehensive review on blastoid MCL in 2020.
KW - Aggressive mantle cell lymphoma
KW - BTK
KW - Blastoid
KW - Ibrutinib
KW - Mantle cell lymphoma
KW - Pleomorphic
KW - Transformation
KW - Venetoclax
UR - http://www.scopus.com/inward/record.url?scp=85089088801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089088801&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2020.06.009
DO - 10.1016/j.hoc.2020.06.009
M3 - Review article
C2 - 32861288
AN - SCOPUS:85089088801
SN - 0889-8588
VL - 34
SP - 941
EP - 956
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 5
ER -